Premium
THE BINDING OF HALOPERIDOL TO HUMAN BLOOD PLATELETS AND INTERACTIONS WITH 5‐HYDROXYTRYPTAMINE AND DOPAMINE
Author(s) -
BOULLIN D.J.,
MOLYNEUX D.,
ROACH B.
Publication year - 1978
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1978.tb07812.x
Subject(s) - haloperidol , platelet , dopamine , chemistry , dopamine antagonist , binding site , pharmacology , endocrinology , medicine , biochemistry
1 The binding of [ 3 H]‐5‐hydroxytryptamine ([ 3 H]‐5‐HT), [ 3 H]‐haloperidol and [ 3 H]‐dopamine to human blood platelets was investigated and the effects of unlabelled haloperidol on [ 3 H]‐5‐HT binding and (+)‐ and (—)‐butaclamol on [ 3 H]‐haloperidol were studied. 2 Scatchard analysis did not show any specific binding of [ 3 H]‐haloperidol or [ 3 H]‐dopamine to platelets, but two binding sites were identified for binding of [ 3 H]‐5‐HT. 3 Unlabelled haloperidol reduced the binding of 5‐HT in concentrations comparable to those inhibiting 5‐HT‐induced platelet aggregation; (+)‐ and (‐)‐butaclamol did not affect the binding of [ 3 H]‐haloperidol. 4 It is concluded that haloperidol binding represents saturation of the platelet membrane, and that the platelet is not a suitable model for investigation of dopamine‐drug interactions.